9
|
Borén J, Watts GF, Adiels M, Söderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Vergès B, Barrett PHR, Taskinen MR. Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol 2015; 35:2218-24. [PMID: 26315407 DOI: 10.1161/atvbaha.115.305614] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Accepted: 08/04/2015] [Indexed: 01/19/2023]
Abstract
OBJECTIVES Patients with obesity and diabetes mellitus have increased risk of cardiovascular disease. A major cause is an atherogenic dyslipidemia related primarily to elevated plasma concentrations of triglyceride-rich lipoproteins. The aim of this study was to clarify determinants of plasma triglyceride concentration. We focused on factors that predict the kinetics of very-low density lipoprotein 1 (VLDL1) triglycerides. APPROACH AND RESULTS A multicenter study using dual stable isotopes (deuterated leucine and glycerol) and multicompartmental modeling was performed to elucidate the kinetics of triglycerides and apoB in VLDL1 in 46 subjects with abdominal obesity and additional cardiometabolic risk factors. Results showed that plasma triglyceride concentrations were dependent on both the secretion rate (r=0.44, P<0.01; r=0.45, P<0.01) and fractional catabolism (r=0.49, P<0.001; r=0.55, P<0.001) of VLDL1-triglycerides and VLDL1-apoB. Liver fat mass was independently and directly associated with secretion rates of VLDL1-triglycerides (r=0.56, P<0.001) and VLDL1-apoB (r=0.53, P<0.001). Plasma apoC-III concentration was independently and inversely associated with the fractional catabolisms of VLDL1-triglycerides (r=0.48, P<0.001) and VLDL1-apoB (r=0.51, P<0.001). CONCLUSIONS Plasma triglyceride concentrations in abdominal obesity are determined by the kinetics of VLDL1 subspecies, catabolism being mainly dependent on apoC-III concentration and secretion on liver fat content. Reduction in liver fat and targeting apoC-III may be an effective approach for correcting triglyceride metabolism atherogenic dyslipidemia in obesity.
Collapse
Affiliation(s)
- Jan Borén
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.).
| | - Gerald F Watts
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Martin Adiels
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Sanni Söderlund
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Dick C Chan
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Antti Hakkarainen
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Nina Lundbom
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Niina Matikainen
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Juhani Kahri
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Bruno Vergès
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - P Hugh R Barrett
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| | - Marja-Riitta Taskinen
- From the Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden (J.B., M.A.); Lipid Disorders Clinic, Metabolic Research Centre, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology (G.F.W., D.C.C., P.H.R.B.) and Faculty of Engineering, Computing and Mathematics (P.H.R.B.), University of Western Australia, Perth, Australia; Heart and Lung Centre, Helsinki University Central Hospital and Research Programs' Unit, Diabetes and Obesity (S.S., N.M., M.-R.T.) and Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital (A.H., N.L.), University of Helsinki, Helsinki, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (N.M., J.K.); and Department of Endocrinology-Diabetology, University Hospital and INSERM CRI 866, Dijon, France (B.V.)
| |
Collapse
|
12
|
Di Filippo M, Marçais C, Charrière S, Marmontel O, Broyer M, Delay M, Merlin M, Nollace A, Valéro R, Lagarde M, Pruneta-Deloche V, Moulin P, Sassolas A. Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects. PLoS One 2014; 9:e96482. [PMID: 24788417 PMCID: PMC4008628 DOI: 10.1371/journal.pone.0096482] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 04/07/2014] [Indexed: 01/27/2023] Open
Abstract
Background Determination of lipoprotein lipase (LPL) activity is important for hyperchylomicronemia diagnosis, but remains both unreliable and cumbersome with current methods. Consequently by using human VLDL as substrate we developed a new LPL assay which does not require sonication, radioactive or fluorescent particles. Methods Post-heparin plasma was added to the VLDL substrate prepared by ultracentrifugation of heat inactivated normolipidemic human serums, diluted in buffer, pH 8.15. Following incubation at 37°c, the NEFA (non esterified fatty acids) produced were assayed hourly for 4 hours. LPL activity was expressed as µmol/l/min after subtraction of hepatic lipase (HL) activity, obtained following LPL inhibition with NaCl 1.5 mmol/l. Molecular analysis of LPL, GPIHBP1, APOA5, APOC2, APOE genes was available for 62 patients. Results Our method was reproducible (coefficient of variation (CV): intra-assay 5.6%, inter-assay 7.1%), and tightly correlated with the conventional radiolabelled triolein emulsion method (n = 26, r = 0.88). Normal values were established at 34.8±12.8 µmol/l/min (mean±SD) from 20 control subjects. LPL activities obtained from 71 patients with documented history of major hypertriglyceridemia showed a trimodal distribution. Among the 11 patients with a very low LPL activity (<10 µmol/l/min), 5 were homozygous or compound heterozygous for LPL or GPIHBP1 deleterious mutations, 3 were compound heterozygous for APOA5 deleterious mutations and the p.S19W APOA5 susceptibility variant, and 2 were free of any mutations in the usual candidate genes. No homozygous gene alteration in LPL, GPIHBP1 and APOC2 genes was found in any of the patients with LPL activity >10 µmol/l/min. Conclusion This new reproducible method is a valuable tool for routine diagnosis and reliably identifies LPL activity defects.
Collapse
Affiliation(s)
- Mathilde Di Filippo
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- * E-mail:
| | - Christophe Marçais
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Sybil Charrière
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Fédération d′endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Oriane Marmontel
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - Martine Broyer
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - Mireille Delay
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Micheline Merlin
- Laboratoire de Biochimie spécialisée, Centre de Biologie Sud, Centre Hospitalier Lyon-Sud, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Axel Nollace
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
| | - René Valéro
- Département de Nutrition, Maladies Métaboliques, Endocrinologie, APHM, Hôpital de la Timone, Aix-Marseille Université, UMR_S 1062, UMR_A1260, Marseille, France
| | - Michel Lagarde
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| | - Valérie Pruneta-Deloche
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| | - Philippe Moulin
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
- Fédération d′endocrinologie, maladies métaboliques, diabète et nutrition, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
| | - Agnès Sassolas
- UF Dyslipidémies Cardiobiologie, Département de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Laboratoire de Biologie Médicale Multi Sites, Hospices Civils de Lyon, Bron, France
- INSERM U1060, INSA de Lyon, INRA U1235, Univ Lyon-1, Université de Lyon, Villeurbanne, Oullins, France
| |
Collapse
|